These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Suppression of Ehrlich subcutaneous solid tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype antibody.
    Author: Saha S, Mondal S.
    Journal: J Exp Clin Cancer Res; 2001 Mar; 20(1):75-84. PubMed ID: 11370834.
    Abstract:
    Mice vaccinated with purified Ehrlich tumor-plasma GT1b admixed with Freund's adjuvant suppressed subcutaneous growth of the same tumor cells inoculated in vivo by 37.9%. The suppression was dose-dependent and was a result of humoral immune response against GT1b. Further, when mice were injected with varying doses of rabbit polyclonal anti-GT1b IgM antibody and challenged with Ehrlich tumor cells subcutaneously, a significant reduction in tumor growth (47.3%) was observed. Again, the suppression was dose-dependent. To strengthen furthier the observed therapeutic potential of this immunogenic GT1b, mice were immunized with anti-idiotype antibodies to GT1b raised in female Sprague Dawley rats by immunization with rabbit anti-GT1b IgM, which is expected to carry the structural image of GT1b. Immunization of mice with this anti-idiotype antibody was observed to suppress Ehrlich subcutaneous solid tumor growth by 60%. The results indicated therapeutic potential of immunogenic tumor-associated ganglioside in solid tumor model.
    [Abstract] [Full Text] [Related] [New Search]